Comment
doi: 10.1159/000512373.
Epub 2020 Dec 15.
High-Dose Omalizumab versus Ligelizumab for the Treatment of Chronic Spontaneous Urticaria: Do Not We Need a Head-To-Head Comparison?
Affiliations
- PMID: 33321510
- DOI: 10.1159/000512373
Item in Clipboard
Comment
High-Dose Omalizumab versus Ligelizumab for the Treatment of Chronic Spontaneous Urticaria: Do Not We Need a Head-To-Head Comparison?
Int Arch Allergy Immunol.
2021.
No abstract available
Comment in
-
Using National Registries to Identify Targeted Therapies for Refractory Urticaria.Int Arch Allergy Immunol. 2021;182(5):459-460. doi: 10.1159/000514689. Epub 2021 Mar 9. Int Arch Allergy Immunol. 2021. PMID: 33690233 No abstract available.
Comment on
-
Ligelizumab Is Superior to Omalizumab for Chronic Spontaneous Urticaria.J Cutan Med Surg. 2020 Mar/Apr;24(2):201-202. doi: 10.1177/1203475419888873. J Cutan Med Surg. 2020. PMID: 32208012 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
